Muciclar (Ambroxol Hydrochloride)

Ambroxol stimulates surfactant production in the lungs and breaks down glycoprotein links within mucus, reducing its viscosity. This enhances mucociliary clearance, allowing secretions to be expelled more easily and improving airway patency.

The dosage of Muciclar is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and overall health status. Patients should follow the specific instructions provided by their prescriber and not adjust the dose on their own.

Safety data for ambroxol during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Muciclar (ambroxol) differs from agents such as N‑acetylcysteine by stimulating surfactant production and having a distinct mechanism that breaks down mucus glycoproteins. Clinical choice depends on factors like patient tolerance, drug interactions, and specific therapeutic goals.

Muciclar should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the product’s stability and efficacy throughout its shelf life.

Muciclar is taken orally, usually as a tablet or liquid, according to the prescriber’s instructions. It should be swallowed with water and can be taken with or without food, unless otherwise advised by the healthcare professional.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, and significant liver enzyme elevations indicating hepatic dysfunction. Patients should seek immediate medical attention if they experience any of these symptoms.

Muciclar is contraindicated in individuals with known hypersensitivity to ambroxol or any of its excipients. Caution is also advised for patients with severe liver or kidney disease, and it should be avoided in those for whom the prescriber determines the risks outweigh the benefits.